skip to Main Content
Who we are

We are an innovative research organization with decades of experience in translating nascent science into leading edge drug discovery programs. We provide expert support across the drug discovery pipeline, offering integrated and stand-alone services to our partners in key therapeutic areas including cancer, neurological disorders, infection, and rare diseases.

Since our establishment as the Italian site of Merck & Co’s Research Laboratories in 2000, we have built an unprecedented track record of success in drug discovery with four therapeutics, discovered by IRBM scientists, currently on the market. Since becoming independent in 2010, we have collaborated with many of the world’s top pharmaceutical and biotechnology companies, as well as global foundations and life science organisations such as MD Anderson Cancer Centre and CHDI Foundation Inc. In 2022, we were selected to join the Chemical Biology Consortium, part of the National Cancer Institute Experimental Therapeutics (Next) Program to help address unmet need in therapeutic oncology.

Our expertise in infectious disease research has been acknowledged with significant funding from the European Investment Bank and our research has led to the out-licencing of fourth-generation Hepatis B Capsid Assembly modulators, which we developed together with our long-standing Italian collaborators the National Institute of Molecular Genetics, and the San Raffaele Hospital.

What we do

Science is our cornerstone. We leverage our shared enthusiasm for science and our dedication to excellence to advance your drug discovery projects. Together, we develop innovative and more effective therapeutics that will improve patients’ quality of life worldwide.

Thanks to our broad expertise, your program can benefit from being developed at IRBM as an integrated project, or through smaller, standalone projects. In the case of integrated programs, we will build clear, actionable go/no-go decision points, and employ a first-to-fail approach to ensure your resources are efficiently managed.

Every day, our passion drives us to continue to learn, develop, and stay at the forefront of science, technology, and innovation.

What we believe in

Our partners are our highest priority. Our ardent drug hunters strive to go above and beyond your expectations. We care about the project you entrust us with and will work to advance your program towards the clinic, without sacrificing scientific rigor. We are committed to delivering scientific excellence in all we do, while operating ethically and working on a foundation of trust with our collaborators.

Our scientists are our greatest asset, so we understand the importance of ensuring they are supported, valued, and nurtured to maintain a strong, motivated team that is adept in accelerating innovation.

We believe in being a sustainable organization and are committed to minimizing our impact on the global environment in all aspects of the company.

Why work with us

We can accelerate your preclinical drug discovery program with our drug hunter expertise in a wide range of modalities, including small molecules, peptides, and antibodies. Our fully integrated solutions and technical competencies provide you with the translational science you need to generate a successful clinical candidate.

All R&D is carried out under one roof in our state-of-the-art facilities, where we provide seamless transitions between disciplines and faster turn-around times. All projects are matched with a team of highly adaptable scientists and a dedicated project representative to create tailor-made solutions, customized to your evolving needs. We provide open and honest communication throughout the lifetime of the project.

SUSTAINABILITY

OUR
HISTORY

Back To Top